Abstract
Purpose
To determine whether pathologic colorectal tumor KRAS mutation status is correlated with progression-free survival (PFS) by imaging after selective internal radiation therapy with Yttrium-90 (SIRT Y90) for metastatic colorectal cancer in the liver (mCRC).
Materials and methods
This was an IRB approved, HIPAA compliant retrospective cohort study. Consecutive patients with unresectable mCRC with documented KRAS mutation status treated at a single center from 2002 to 2013 with SIRT Y90 were investigated. Treatment response was compared between KRAS wild-type (wt) and mutant (mut) using an anatomic tumor response criteria based on RECIST 1.0. Kaplan–Meier estimation and Cox regression analysis were used to measure progression-free survival (PFS) and to assess independent prognostic factors for PFS.
Results
82 of 186 patients met review criteria. 33 (40.2%) patients were identified as KRAS mut. PFS was longer in KRAS wt (median 166 days [95% CI 96–258 days]) vs. mut (median 91 days [95% CI 79–104 days], p = 0.002). KRAS mut patients were 1.48 times more likely to progress at first follow-up imaging than wt (95% CI 1.06–2.08, p = 0.024). Univariate analysis identified high pre-SIRT Y90 INR, KRAS wt, any use of anti-EGFR therapy, and post-SIRT Y90 chemotherapy as prognostic factors for longer PFS. In multivariate analysis, only KRAS wt was an independent prognostic factor for longer PFS (RR: 1.80 [95% CI 1.08–2.99], p = 0.024).
Conclusion
Longer PFS is associated with KRAS wt vs. mut following SIRT Y90.
Similar content being viewed by others
References
Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis 6(1):479–507
Bos JL, Fearon ER, Hamilton SR, et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327(6120):293–297
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765
Kim ST, Park KH, Kim JS, Shin SW, Kim YH (2013 ) Impact of KRAS mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapy. Cancer Res Treat 45(1):55–62. PMCID: PMC3629364
Andreyev HJ, Norman AR, Cunningham D, et al. (2001) Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer 85(5):692–696. PMCID: PMC2364126
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90(9):675–684
Richman SD, Seymour MT, Chambers P, et al. (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27(35):5931–5937
Lièvre A, Bachet J-B, Le Corre D, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995
Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634
Van Cutsem E, Köhne C-H, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417
Bokemeyer C, Bondarenko I, Makhson A, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671
Douillard J-Y, Siena S, Cassidy J, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705
Peeters M, Price TJ, Cervantes A, et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31):4706–4713
Laimer K, Spizzo G, Gastl G, et al. (2007) High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 43(2):193–198
Sahlberg SH, Gustafsson A-S, Pendekanti PN, Glimelius B, Stenerlöw B (2014) The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol 35(4):3525–3534. PMCID: PMC3980041
Freudlsperger C, Horn D, Weißfuß S, et al. (2015) Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer 136(12):2775–2785
Stegeman H, Span PN, Kaanders JHAM, Bussink J (2014) Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev 40(10):1182–1191
Akinwande O, Philips P, Scoggins CR, et al. (2016) Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol 113(4):443–448
Hipps D, Ausania F, Manas DM, Rose JDG, French JJ (2013) Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg World J Hepat Pancreat Biliary Surg 2013:570808. PMCID: PMC3830800
Lahti S, Xing M, Zhang D et al. KRAS Status as an independent prognostic factor for survival after yttrium-90 radioembolizatoin therapy for unresectable colorectal cancer liver metastases. JVIR (In Press)
Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R et al. (2015) Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg PMID: 26038887
Lewandowski RJ, Sato KT, Atassi B, et al. (2007) Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30(4):571–592
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278. PMID: 16923973
Kooby DA, Egnatashvili V, Srinivasan S, et al. (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224–230
Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ (2013) LiverTox: a website on drug-induced liver injury. Hepatology 57(3):873–874
Reimers MS, Zeestraten ECM, Kuppen PJK, Liefers GJ, van de Velde CJH (2013) Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep 1(3):166–183. PMCID: PMC3937997
Petrioli R, Licchetta A, Roviello G, et al. (2012) CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest 30(1):65–71
Gulec SA, Suthar RR, Barot TC, Pennington K (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38(7):1289–1295
Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S (2011) Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol 9(1):86
Zalom M, Yu R, Friedman M, Bresee C, Waxman A (2012) FDG PET/CT as a prognostic test after 90Y radioembolization in patients with metastatic hepatic disease. Clin Nucl Med 37(9):862–865
Annunziata S, Treglia G, Caldarella C, Galiandro F (2014) The Role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. Sci World J 2(2014):e879469
Zerizer I, Al-Nahhas A, Towey D, et al. (2012) The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 39(9):1391–1399
Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF (2013) Standards of practice in transarterial radioembolization. Cardiovasc Interv Radiol 36(3):613–622
Skougaard K, Johannesen HH, Nielsen D et al. (2014) CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Med. 3(5):1294–1301. PMCID: PMC4302679
Toulany M, Dittmann K, Krüger M, Baumann M, Rodemann HP (2005) Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3 K-AKT pathway. Radiother Oncol J Eur Soc Ther Radiol Oncol 76(2):143–150
Toulany M, Kasten-Pisula U, Brammer I, et al. (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res Off J Am Assoc Cancer Res 12(13):4119–4126
Minjgee M, Toulany M, Kehlbach R, Giehl K, Rodemann HP (2011) K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 81(5):1506–1514
Wang M, Kern AM, Hülskötter M et al. (2014) EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res 74(10):2825–2834. PMCID: PMC4278592
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have no financial or other disclosures relationship with any commercial organization that may have a direct or indirect interest in this manuscript. There is no conflict of interest to declare for this manuscript.
Information concerning grants
None applicable.
Rights and permissions
About this article
Cite this article
Magnetta, M.J., Ghodadra, A., Lahti, S.J. et al. Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdom Radiol 42, 451–459 (2017). https://doi.org/10.1007/s00261-016-0875-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-016-0875-8